KRAS G12D | ApexOnco - Clinical Trials news and analysis

x

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Deals

7 February 2024

Jazz joins the KRAS band with Redx deal

Boy jumping over high jump with bar set low

Conferences Trial results

18 October 2023

ESMO 2023 – Jiangsu Hengrui sets a low bar in KRAS G12D inhibition

Conferences Data insights

16 October 2023

Triple meeting 2023 – Revolution’s KRAS revolution promise draws fans

Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients.

Trial results

20 September 2023

Revolution in the next KRAS battleground

Subscribe to KRAS G12D